

Disclaimer :

The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.

M. 8556 - CARLYLE / GTCR / ALBANY MOLECULAR RESEARCH

SECTION 1.2

Description of the concentration

Carlyle Partners VI, L.P. (“**CP VI**”), a fund managed by affiliates of The Carlyle Group (“**Carlyle**”), and affiliates of GTCR LLC (“**GTCR**”) intend to acquire all of the issued and outstanding shares in Albany Molecular Research, Inc. (“**AMRI**”) (the “**Proposed Transaction**”). As a result of the Proposed Transaction, CP VI and GTCR will jointly control AMRI. The nature of the businesses of the parties is as follows:

- Carlyle is a global alternative asset manager, which manages funds that invest globally across four investment disciplines: (i) Corporate Private Equity; (ii) Real Assets; (iii) Global Market Strategies; and (iv) Solutions.
- GTCR is a private equity firm founded focused on investing in growth companies in the Financial Services & Technology, Healthcare, Technology, Media & Telecommunications and Growth Business Services industries.
- AMRI is a global contract research and manufacturing organization providing customers integrated drug discovery, development, and manufacturing services.

Commission européenne, DG COMP MERGER REGISTRY, 1049 Bruxelles, BELGIQUE
Europese Commissie, DG COMP MERGER REGISTRY, 1049 Brussel, BELGIË

Tel: +32 229-91111. Fax: +32 229-64301. E-mail: COMP-MERGER-REGISTRY@ec.europa.eu.